Neurological diseases in pregnancy: an overview. Foreword.

K. Digre,M. Varner

DOI: https://doi.org/10.1097/GRF.0b013e31828f9b78

2013-06-01

Abstract:

What problem does this paper attempt to address?

Metabolic Pathway of Osilodrostat in Equine Urine Established through High-resolution Mass Spectrometric Characterization for Doping Control

Hideaki Ishii,Ryo Shigematsu,Shunsuke Takemoto,Yuhiro Ishikawa,Fumiaki Mizobe,Motoi Nomura,Daisuke Arima,Hirokazu Kunii,Reiko Yuasa,Takashi Yamanaka,Sohei Tanabe,Shun-ichi Nagata,Masayuki Yamada,Gary Ngai-Wa Leung

DOI: https://doi.org/10.2174/0113892002325954240903062440

2024-09-05

Current Drug Metabolism

Abstract:Objective: Osilodrostat, used to treat Cushing's disease, exhibits an anabolic effect, leading to its classification as a prohibited substance in horseracing and equestrian sports. This study reports the characterization of osilodrostat metabolites in horse urine and elucidates its metabolic pathways for the first time for doping control purposes. Methods: Osilodrostat was administered nasoesophageally to four thoroughbreds (one gelding and three mares) at a dose of 50 mg each. Potential metabolites were extensively screened via our developed generic approach employing differential analysis to identify metabolites. Specifically, high-resolution mass spectral data were compared between pre- and post-administration samples on the basis of criteria of fold-changes of peak areas and their P values. Potential metabolite candidates were further identified through mass spectral interpretations using product ion scan data. Results: A total of 37 metabolites were identified after comprehensive analysis. Osilodrostat was predominantly metabolized into a mono-hydroxylated form M1c (~40%) alongside osilodrostat glucuronide M2 (~17%). Given their longest detection time (2 weeks after administration) and the identification of several conjugates of osilodrostat and M1c, including a novel conjugate of riburonic acid, we recommend monitoring both osilodrostat and M1c after hydrolysis during the screening stage. However, only osilodrostat can be used for confirmation because of the availability of a reference material. Conclusion: It is advisable to screen for both osilodrostat and its mono-hydroxylated metabolite M1c to effectively monitor horse urine for the potential misuse or abuse of osilodrostat. For suspicious samples, confirmation of osilodrostat using its reference material is required.

pharmacology & pharmacy,biochemistry & molecular biology
Neuropsychological Test Performance Among Caribbean-born and U.S.-born African American Elderly: The Role of Age, Education and Reading Level

D. Byrd,Danurys L Sanchez,J. Manly

DOI: https://doi.org/10.1080/13803390490919353

2005-11-01

Journal of Clinical and Experimental Neuropsychology

Abstract:Within-group variation is an important yet under-studied component of cross-cultural neuropsychology. The current study explored this potential source of variation in a neurologically healthy African American elderly sample by comparing the neuropsychological test performance of nondemented groups of Caribbean-born and U.S.-born African American elders who live in New York City. Caribbean-born elders resided in the U.S. for a mean of 41.5 years (SD = 17.0). Results indicate that in general, Caribbean-born elders in this cohort did not demonstrate a unique cognitive testing profile from U.S.-born African American elders. However, the Caribbean-born group demonstrated a higher quality of education than their U.S.-born counterparts. The influence of demographic factors (i.e., age and education) on neuropsychological test performance was markedly attenuated in Caribbean-born elders though reading level was the strongest predictor of test performance for all elders, regardless of birthplace.
Pharmacokinetic study of osilodrostat and identification of mono‐hydroxylated metabolite in equine plasma for the purpose of doping control

Hideaki Ishii,Yuhiro Ishikawa,Fumiaki Mizobe,Motoi Nomura,Takashi Yamanaka,Sohei Tanabe,Shun‐ichi Nagata,Masayuki Yamada,Gary Ngai‐Wa Leung

DOI: https://doi.org/10.1002/rcm.9695

IF: 2.586

2024-01-18

Rapid Communications in Mass Spectrometry

Abstract:Rationale Osilodrostat is an inhibitor of 11‐beta‐hydroxylase (CYP11B) and is used for the treatment of Cushing's disease but also categorized as an anabolic agent. The use of osilodrostat is prohibited in horseracing and equestrian sports. To the best of our knowledge, this is the first metabolic study of osilodrostat in equine plasma. Methods Potential metabolites of osilodrostat were identified by differential analysis using data acquired from pre‐ and post‐administration plasma samples after protein precipitation with liquid chromatography electrospray ionization high‐resolution mass spectrometry (C–HRMS). For quantification of osilodrostat, a strong cation exchange solid‐phase extraction was employed, and the extracts were analyzed using LC/ESI–triple quadrupole tandem mass spectrometry (LC/ESI–QqQ‐MS/MS) to establish its elimination profile. Such extracts were further analyzed using LC/ESI–HRMS to investigate the detectability of osilodrostat and its identified mono‐hydroxylated metabolite over a 2‐week sampling period. Results Mono‐hydroxylated osilodrostat was identified based on the differential analysis and mass spectrometric interpretations, and it was found to be the most abundant metabolite in plasma. Elimination profile of osilodrostat in plasma was successfully established over the 24‐h post‐administration period. Both osilodrostat and its mono‐hydroxylated metabolite were detected up to the last sampling point at 2 weeks using HRMS, and osilodrostat could be confirmed up to 8‐day post‐administration with its reference material using HRMS as well. Conclusions For doping control, screening of both the parent drug osilodrostat and its mono‐hydroxylated metabolite in equine plasma would be recommended due to their extended detection windows of up to 2 weeks. Given the availability of reference material for potential confirmation in forensic samples, osilodrostat is considered the most appropriate monitoring target.

spectroscopy,chemistry, analytical,biochemical research methods
Broad‐spectrum and sensitive screening of more than 1000 compounds in equine urine using liquid chromatography/high‐resolution mass spectrometry

Taiga Uchida,Takaya Kisugi,Hideaki Ishii,Masayuki Yamada,Kenji Kinoshita,Gary Ngai‐Wa Leung

DOI: https://doi.org/10.1002/rcm.9856

IF: 2.586

2024-06-30

Rapid Communications in Mass Spectrometry

Abstract:Rationale To uphold the integrity of horseracing and equestrian sports, it is critical for an equine doping control laboratory to develop a comprehensive screening method to cover a wide range of target substances at the required detection levels in equine urine. Methods The procedure involved the enzymatic hydrolysis of 3 mL urine samples followed by solid‐phase extraction using HF Bond Elut C18 cartridge. The resulting extracts were then separated on a C18 reversed‐phase column and analyzed using liquid chromatography/high‐resolution mass spectrometry (LC/HRMS) in both electrospray ionization positive and negative modes in two separate injections. The analytical data were obtained in full scan and product ion scan (PIS) modes in an 11 min LC run. Results The method can detect 1011 compounds (in both positive and negative ion modes). Over 95% of the target compounds have limits of detections (LODs) ≤10 ng/mL, and more than 50% of the LODs are ≤0.5 ng/mL. The lowest LOD can reach down to 0.01 ng/mL. The applicability of the method was demonstrated by the successful detection of prohibited substances in overseas and domestic equine urine samples. Conclusions We have successfully developed a regular screening method for equine urine samples that can detect more than 1000 compounds at sub‐ppb levels in both positive and negative ion modes with full scan and PIS using LC/HRMS. Furthermore, this method can theoretically be expanded to accommodate an unlimited number of prohibited substances in full‐scan mode.

spectroscopy,chemistry, analytical,biochemical research methods
Direct injection horse urine analysis for the quantification and identification of threshold substances for doping control. III. Determination of salicylic acid by liquid chromatography/quadrupole time-of-flight mass spectrometry

A. Vonaparti,E. Lyris,I. Panderi,M. Koupparis,C. Georgakopoulos

DOI: https://doi.org/10.1007/s00216-009-3047-7

2009-09-08

Analytical and Bioanalytical Chemistry

Abstract:In equine sport, salicylic acid is prohibited with a threshold level of 750 µg mL−1 in urine; hence, doping control laboratories have to establish quantitative and qualitative methods for its determination. A simple and rapid liquid chromatographic/mass spectrometric method was developed and validated for the quantification and identification of salicylic acid. Urine samples after 900-fold dilution and addition of the internal standard (4-methylsalicylic acid) were directly injected to the liquid chromatography/quadrupole time-of-flight mass spectrometry system. Electrospray ionization in negative mode with full scan acquisition mode and product ion scan mode were chosen for the quantification and identification of salicylic acid, respectively. Run time was 2.0 min. The tested linear range was 2.5–50 µg mL−1 (after 100-fold sample dilution). The relative standard deviations of intra- and inter-assay analysis of salicylic acid in horse urine were lower than 2.5% and 2.8%, respectively. Overall accuracy (relative percentage error) was less than 3.3%. Method was applied to two real samples found to be positive for salicylic acid, demonstrating simplicity, accuracy, and selectivity.
A Broad-Spectrum Peptide Screening Method Using an Optimized Solid-Phase Extraction and Liquid Chromatography–High-Field Asymmetric Ion Mobility Spectrometry–Mass Spectrometry for Doping Control in Equine Urine

Kohei Ohnuma,Misato Kodaira-Hirano,Michiko Bannai,Yoshibumi Shimizu,Masayuki Yamada,Kenji Kinoshita,Gary Ngai-Wa Leung,Hideaki Ishii

DOI: https://doi.org/10.1039/d4ay01477d

IF: 3.1

2024-10-31

Analytical Methods

Abstract:The abuse of prohibited peptide-based drugs with a broad spectrum of chemical characteristics poses a significant concern for the horseracing industry. Recently, there has been a notable increase in positive cases of small-peptide drugs reported in equine and canine sports. In addition to small peptides, large peptides (over 2 kDa) with structural diversity have also entered the market in increasing numbers as drugs for humans and livestock. However, the simultaneous analysis of both small- and large-peptide-based drugs is still challenging. In this study, a screening method was developed to cover 74 analytes, including peptides, their catabolites, and/or their mimetics, with molecular weights ranging from 0.3 kDa to greater than 5 kDa. The simultaneous extraction of both small and large peptides was achieved using a weak cation-exchange solid-phase extraction cartridge with a mixture of different pore sizes (suitable for large peptides), followed by analysis using liquid chromatography high-field asymmetric ion mobility spectrometry tandem mass spectrometry (LC–FAIMS–MS/MS). For method validation, the limits of detection (LoDs), reproducibility, recovery, matrix effect, selectivity, and carryover were evaluated. Remarkably, the LoDs of ~80% of the analytes were less than or equal to 50 pg ml-1, with the lowest LoD (1 pg ml-1) being observed for selected peptides in horse urine. These results indicate a substantial advancement in achieving comprehensive coverage for both small and large peptides with high sensitivity for the purpose of doping control in horseracing and equestrian sports

spectroscopy,chemistry, analytical,food science & technology
Detection of FG‐4592 and metabolites in equine plasma, urine and hair following oral administration

Charlotte Cutler,Marjaana Viljanto,Polly Taylor,Pamela Hincks,Jocelyn Habershon‐Butcher,Bobby Gray,James Scarth

DOI: https://doi.org/10.1002/dta.3643

2024-01-14

Drug Testing and Analysis

Abstract:Hypoxia‐inducible factor inhibitors, including FG‐4592, are prohibited in sports, and thus identifying the best targets for their detection in doping control is essential. Analysis of equine urine, plasma and hair showed that the parent drug was the best target for detection of oral administration in all three matrices. FG‐4592 is a hypoxia‐inducible factor inhibitor that has been approved for therapeutic use in some countries. This class of compounds can increase the oxygen carrying capacity of the blood and thus have the potential to be used as performance enhancing agents in sports. The purpose of this study was to investigate the detection of FG‐4592 and metabolites in equine plasma and mane hair following a multiple dose oral administration to two Thoroughbred racehorses, to identify the best analytical targets for doping control laboratories. Urine samples were also analysed, and the results compared to previously published urine data. Liquid chromatography‐high resolution mass spectrometry was used for metabolite identification in urine and plasma. Liquid chromatography–tandem mass spectrometry was used for full sample analysis of urine, plasma and hair samples and generation of urine and plasma profiles. FG‐4592 and a mono‐hydroxylated metabolite were detected in plasma. FG‐4592 was detected with the greatest abundance and gave the longest duration of detection, up to 312 h post‐administration, and would be the recommended target in routine doping samples. FG‐4592 was detected in all mane hair samples collected post‐administration, up to 166 days following the final dose, showing extended detection can be achieved with this matrix. To the best of the authors' knowledge, this is the first report of FG‐4592 and metabolites in equine plasma and hair samples. Urine results were consistent with the previously published data, with FG‐4592 offering the best target for detection and longest detection periods.

pharmacology & pharmacy,biochemical research methods,chemistry, analytical
Brain Microdialysis Study of Meropenem in Two Patients with Acute Brain Injury

C. Dahyot-fizelier,I. Timofeev,S. Marchand,Peter Hutchinson,B. Debaene,D. Menon,O. Mimoz,A. Gupta,W. Couet

DOI: https://doi.org/10.1128/AAC.01725-09

IF: 5.938

2010-06-01

Antimicrobial Agents and Chemotherapy

Abstract:ABSTRACT Concentrations of unbound meropenem in the cerebral extracellular fluid (ECF) of two patients with acute brain injury were assessed by microdialysis. Brain ECF unbound-meropenem concentrations were lower than serum unbound-meropenem concentrations, with brain-to-serum area under the concentration-time curve ratios of 0.73 and 0.14. A pharmacokinetic model was developed to fit the experimental data adequately.
A rapid and sensitive method for the quantitative analysis of ibuprofen and its metabolites in equine urine samples by gas chromatography with tandem mass spectrometry.

J. Namieśnik,E. Kłodzińska,Emilia Waraksa,M. Woźniak,R. Wrzesień,B. Bobrowska-Korczak

DOI: https://doi.org/10.1002/jssc.201800614

IF: 3.614

2018-08-28

Journal of Separation Science

Abstract:Ibuprofen is widely used in human and veterinary medicine for the treatment of chronic pain as well as rheumatic and musculoskeletal disorders. However, the analgesic and anti-inflammatory properties of Ibuprofen have contributed to frequent drug abuse in equestrian sports. A sensitive and rapid gas chromatography with tandem mass spectrometry based method with a simple liquid-liquid extraction and derivatization requiring 200 μL volume of sample and 2 mL of extraction solvent for the simultaneous determination of ibuprofen and its metabolites was developed. The proposed procedure was optimized and validated according to the principles for bioanalytical methods. The assay achieved satisfactory validation parameters, namely, recovery (92.2-105%), interday accuracy (92.5-106%), and precision (0.3-4.4%) for all investigated compounds as well as limits of quantification of 50 ng/mL for ibuprofen, 2-hydroxyibuprofen, and carboxyibuprofen, 25 ng/mL for 1-hydroxyibuprofen and 100 ng/mL for 3-hydroxyibuprofen. The applicability of the method was evaluated by the analysis of five real urine samples collected from different horses after drug administration. In view of the low limits of quantification, high selectivity, repeatability, and recovery, the procedure can be utilized for laboratory applications, including the control of ibuprofen abuse in equestrian sports for anti-doping purposes and drug/pharmaceutical mentality investigations.

Chemistry,Medicine
Investigation Into the Equine Metabolism of Phosphodiesterase‐4 Inhibitor Roflumilast for Potential Doping Control

Moses Philip,Abdul Khader Karakka Kal,Michael Benedict Subhahar,Tajudheen K. Karatt,Fatma Mohammed Graiban,Meleparappil Muhammed Ajeebsanu,Marina Joseph,Shantymol V. Jose

DOI: https://doi.org/10.1002/dta.3822

2024-11-27

Drug Testing and Analysis

Abstract:This paper describes the metabolic transformation of the phosphodiesterase‐4 inhibitor Roflumilast in thoroughbred horses after oral intake. Additionally, it presents in vitro experiments utilizing equine liver microsomes and Cunninghamella elegans. Plausible structures of identified metabolites were proposed through liquid chromatography‐high resolution mass spectrometry. The data reported here could assist in detecting illicit uses of Roflumilast in competitive sports. The phosphodiesterase 4 (PDE4) inhibitors constitute a relatively modern class of medications that are known for inducing bronchodilation and exhibiting anti‐inflammatory properties within the body. Due to these properties, there is concern regarding their potential misuse as performance‐enhancing substances in competitive sports. This study delves into the metabolic conversion of roflumilast in thoroughbred horses following oral administration and in vitro experimentation using equine liver microsomes and Cunninghamella elegans. High‐performance liquid chromatography coupled with a Q Exactive Orbitrap mass spectrometer (HPLC‐HRMS) was employed for analysis. The investigation identified 10 metabolites of roflumilast, including six phase I and four phase II metabolites from in vivo studies, and 11 metabolites from in vitro studies, consisting of eight phase I and three phase II metabolites. The identified biotransformation products encompassed processes such as hydroxylation, chlorine substitution, methylation, N‐oxide formation, and even the dissociation of methylenecyclopropane and difluoromethane. Furthermore, the study identified three glucuronic acid and one sulfonic acid conjugated phase II metabolites of the investigated drug candidate. The aforementioned findings contribute to the detection and comprehension of the unauthorized utilization of roflumilast in equestrian sports.

pharmacology & pharmacy,biochemical research methods,chemistry, analytical
Long-term followup of patients less than 30 years old with transitional cell carcinoma of bladder.

I. Madgar,B. Goldwasser,O. Nativ,Yacov Hanani,Paul Jonas

DOI: https://doi.org/10.1016/S0022-5347(17)42721-2

1988-05-01

Abstract:
Mentoring Diversity. Serving a diverse patient population calls for diverse leadership.

L. Ambrose

2003-09-01

Abstract:
Detection of methandienone and its metabolites in equine urine, plasma and hair following a multidose oral administration

Marjaana Viljanto,Catherine Love,Daniel White,Jocelyn Habershon‐Butcher,Pamela Hincks,Bobby Gray,James Scarth

DOI: https://doi.org/10.1002/dta.3633

2024-01-19

Drug Testing and Analysis

Abstract:Metabolism and detection of methandienone in urine are well established in horses, but there is limited knowledge about its metabolites in plasma and no information about its detection in hair. Following an oral administration, nine Phase I metabolites were observed in plasma, and the longest detection time was achieved by targeting the parent compound and the mono‐hydroxylated metabolite. In hair, the parent compound and hydroxylated metabolites were detected and the mono‐hydroxylated offered the longest detection time. Methandienone is an anabolic‐androgenic steroid that is prohibited in equine sports due to its potential performance enhancing properties. Metabolism and detection of methandienone in equine urine have been investigated comprehensively in literature; however, there is a limited knowledge about its metabolites in equine plasma and no information about its detection in equine hair. Following a multi‐dose oral administration of methandienone to two Thoroughbred horses, 17‐epimethandienone, methyltestosterone, two mono‐hydroxylated, two di‐hydroxylated and three 17α‐methylandrostanetriol metabolites were detected in plasma. The majority of these were present as free analytes, whilst the mono‐hydroxylated metabolites and one isomer of 17α‐methylandrostanetriol were partially conjugated. Estimated peak concentrations of methandienone were 6,000 and 11,100 pg/ml; meanwhile, they were 25.4 and 40.5 pg/ml for methyltestosterone. The most abundant analyte in the post‐administration plasma samples of both horses was the mono‐hydroxylated metabolite; however, the parent compound provided the longest detection (up to 96 h). Screening analysis of hair enabled the detection of methandienone in mane hair samples only, for up to 3 months. Its mono‐ and di‐hydroxylated metabolites were detected with greater peak responses for up to 6 months post‐administration in both mane and tail samples, showing that these metabolites could be better analytical targets for hair analysis when administered orally. A follow‐up methodology with an extensive wash procedure confirmed the presence of methandienone and its metabolites in a number of post‐administration hair samples. Final wash samples were also analysed to assess the degree of internal incorporation (via bloodstream) against possible external deposition (via sweat/sebum).

pharmacology & pharmacy,biochemical research methods,chemistry, analytical
Doping control analysis of myo‐inositol trispyrophosphate and 10 bisphosphonates in equine plasma by ion chromatography–mass spectrometry and its application to clodronic acid horse administration

April Sum Yee Wong,Bruce Pui‐Nam Yuen,Celia Oi Ling Wong,Fred Ka‐Wai Kong,Yat‐Ming So,Wai Him Kwok,Lydia Brooks,Terence See Ming Wan,Emmie Ngai‐Man Ho

DOI: https://doi.org/10.1002/dta.3753

2024-06-26

Drug Testing and Analysis

Abstract:Bisphosphonates and myo‐inositol trispyrophosphate (ITPP) are two classes of difficult‐to‐detect polar drugs that are prohibited under the rules of racing. This paper describes an efficient ion chromatography high‐resolution mass spectrometry (IC‐HRMS) method for the simultaneous detection of ITPP and 10 bisphosphonates at sub‐parts‐per‐billion (ppb) to low‐ppb levels in equine plasma after solid‐phase extraction (SPE) and its application to an administration study of clodronic acid in horses. Bisphosphonates and myo‐inositol trispyrophosphate (ITPP) are two classes of difficult‐to‐detect polar drugs that are prohibited under the rules of racing. ITPP is a drug capable of increasing the amount of oxygen in hypoxic tissues, and studies have shown that administration of ITPP increases the maximal exercise capacity in mice. The properties of ITPP make it an ideal candidate as a doping agent to enhance performance in racehorses. In recent years, ITPP had indeed been detected in racehorses and confiscated items. As for bisphosphonates, it is especially critical to control their use as since February 2019, the International Agreement on Breeding, Racing and Wagering (IABRW) by the International Federation of Horseracing Authorities (IFHA) had identified specific conditions on which bisphosphonates should not be administered to a racehorse. A recent review of literature shows that there is yet a simultaneous screening method for detecting ITPP and bisphosphonates in equine samples. This paper describes an efficient ion chromatography high‐resolution mass spectrometry (IC‐HRMS) method for the simultaneous detection of ITPP and 10 bisphosphonates at sub‐parts‐per‐billion (ppb) to low‐ppb levels in equine plasma after solid‐phase extraction (SPE) and its application to an administration study of clodronic acid in horses.

pharmacology & pharmacy,biochemical research methods,chemistry, analytical
Identification and differentiation of somapacitan, a long-acting growth hormone derivative, and recombinant human growth hormone in equine plasma by LC-HRMS for doping control purpose

Yoshibumi Shimizu,Michiko Sugai-Bannai,Kazunobu Saito,Misato Hirano-Kodaira,Gary Ngai-Wa Leung

DOI: https://doi.org/10.1016/j.ghir.2024.101628

IF: 2.125

2024-11-13

Growth Hormone & IGF Research

Abstract:Somapacitan, a long-acting growth hormone derivative, and recombinant human growth hormone (rhGH) are protein-based drugs generally used to treat growth disorders and GH deficiency in humans. Due to their potential to enhance the horse performance, the use of these drugs is prohibited at-all-times by the International Federation of Horseracing Authorities for horseracing and the Fédération Equestre Internationale for equestrian sports. In this study, we developed a test method for the identification and differentiation of somapacitan and rhGH in equine plasma by using liquid chromatography high-resolution mass spectrometry (LC–HRMS). The method involved C4 solid-phase extraction after ammonium sulfate precipitation, followed by chloroform/methanol precipitation, trypsin digestion, and analysis by LC-HRMS. The discriminative identification of somapacitan and rhGH was successfully achieved through the detection of their respective unique T10 peptide fragments. Noteworthy, the T10 peptide fragment of somapacitan was detected with its side chain structure remaining intact. The limit of identification (confirmation) (LOI) was determined to be 5 ng/mL for somapacitan and 2 ng/mL for rhGH in equine plasma, while the limit of detection (LOD) was 5 ng/mL for somapacitan and 1 ng/mL for rhGH. Furthermore, using the peptide fragments T1, T8, and T9 (which are shared between somapacitan and rhGH), the presence of somapacitan in equine plasma could be confirmed with higher sensitivity, achieving down to LOIs of 2 ng/mL and LODs of 1 ng/mL. The method was validated with respect to specificity, identification capability, robustness, precision, and reproducibility, paving the way for the analysis of post-administration samples from our already planned administration trials and future potential positive cases.

cell biology,endocrinology & metabolism
Model-based boundary estimation of complex objects using hierarchical active surface templates

J. Snell,M. Merickel,J. Ortega,J. Goble,J. Brookeman,N. Kassell

DOI: https://doi.org/10.1016/0031-3203(95)00021-Q

IF: 8

1995-10-01

Pattern Recognition

Abstract:
Development and validation of general plasma screening method for performance enhancing drugs in racehorses utilizing liquid chromatography-high-resolution mass spectrometry (LC-HRMS)

Izabela Lomnicka,Saurabh Dubey,Pamela Waller,Dharmikkumar Vora,Levent Dirikolu

DOI: https://doi.org/10.1002/dta.3774

2024-07-29

Abstract:The screening of drugs in plasma and urine often requires initial extraction (such as liquid-liquid extraction and solid-phase extraction) before the samples are submitted to instrumental analyses. These extraction procedures are often laborious and time-consuming. In this manuscript, a high-throughput automated assay based on liquid chromatography-high-resolution mass spectrometry (LC-HRMS) suitable for use as an initial testing procedure covering multiple classes of compounds prohibited in horse racing is described. The assay requires a 600-μL plasma aliquot, which is subjected to solid phase extraction (SPE) using OASIS HLB 96-well SPE with Biotage Extrahera system, evaporation, and reconstitution in a 96-well collection plate. LC-HRMS analyses were carried out on a Thermo Q-Exactive Mass spectrometer coupled with Thermo UHPLC system equipped with Thermo Accela ALS 2.4.0 autosampler linked to ACE Excel column. Drug targets were detected by retention time and accurate mass, with a mass tolerance window of 5 ppm in positive and negative ionization mode. The screening method was validated for over 300 drug targets in a 13-min run. Validation data including sensitivity, specificity, extraction recovery, and precision are presented. As the method employs full-scan mass spectrometry, unlimited number of drug targets can theoretically be incorporated into this method.
3-Methoxytyrosine as an indicator of dopaminergic manipulation in equine plasma

Bethany Keen,Adam Cawley,Brian Reedy,Glenys Noble,Jaymie Loy,Shanlin Fu

DOI: https://doi.org/10.1016/j.jchromb.2023.123652

2023-04-01

Abstract:The use of catechol-O-methyltransferase inhibitors may mask doping agents, primarily levodopa, administered to racehorses and prolong the stimulating effects of dopaminergic compounds such as dopamine. It is known that 3-methoxytyramine is a metabolite of dopamine and 3-methoxytyrosine is a metabolite of levodopa thus these compounds are proposed to be potential biomarkers of interest. Previous research established a urinary threshold of 4,000 ng/mL for 3-methoxytyramine to monitor misuse of dopaminergic agents. However, there is no equivalent biomarker in plasma. To address this deficiency a rapid protein precipitation method was developed and validated to isolate target compounds from 100 µL equine plasma. A liquid chromatography-high resolution accurate mass (LC-HRAM) method using an IMTAKT Intrada amino acid column provided quantitative analysis of 3-methoxytyrosine (3-MTyr) with lower limit of quantification of 5 ng/mL. Reference population profiling (n = 1129) investigated the expected basal concentrations for raceday samples from equine athletes and showed a right-skewed distribution (skewness = 2.39, kurtosis = 10.65) which resulted from large variation (RSD = 71%) within the data. Logarithmic transformation of the data provided a normal distribution (skewness = 0.26, kurtosis = 3.23) resulting in the proposal of a conservative threshold for plasma 3-MTyr of 1,000 ng/mL at a 99.995% confidence level. A 12-horse administration study of Stalevo® (800 mg L-DOPA, 200 mg carbidopa, 1600 mg entacapone) revealed elevated 3-MTyr concentrations for 24-hours post-administration.
Analysis of corticosteroids in equine urine by liquid chromatography–mass spectrometry

P.W Tang,W.C Law,Terence S.M Wan

DOI: https://doi.org/10.1016/s0378-4347(00)00613-7

2001-04-01

Abstract:A liquid chromatography-mass spectrometry (LC-MS) method for the analysis of corticosteroids in equine urine was developed. Corticosteroid conjugates were hydrolysed with beta-glucuronidase; free and enzyme-released corticosteroids were then extracted from the samples with ethyl acetate followed by a base wash. The isolated corticosteroids were detected by LC-MS and confirmed by LC-MS-MS in the positive atmospheric pressure chemical ionisation mode. Twenty-three corticosteroids (comprising hydrocortisone, deoxycorticosterone and 21 synthetic corticosteroids), each at 5 ng/ml in urine, could easily be analysed in 10 min.
A Comprehensive and High-Throughput Screening Multiple Prohibited Substances Method by UPLC-QE Plus-HRMS and HPLC-QQQ-MS in Human Urine for Doping Control

Yunxi Liu,Tianyu Dong,Kuan Yan,Zhanliang Wang,Genye He,Yufeng Zhang,Congcong Ma,Lu Liu,Wei Chang,Lisi Zhang

DOI: https://doi.org/10.1039/d3ay00424d

IF: 3.1

2023-06-09

Analytical Methods

Abstract:Since the World Anti-Doping Agency's (WADA) Prohibited List is updated on an annual basis, screening methods must be continually adapted to align with these changes. In accordance with Technical Document -MRPL 2022, a new combined, comprehensive, rapid and high-throughput doping control screening method for the analysis of 350 substances with different polarities in human urine using Ultra-High Performance Liquid Chromatography coupled with Q Exactive Plus Hybrid Quadrupole-Orbitrap Mass Spectrometer (UPLC-QE Plus-HRMS) and Ultra-High Performance Liquid Chromatography coupled with Triple Quadrupole Mass Spectrometer (UPLC-QQQ-MS) has been developed. The limits of detection were in the range of 0.12-50 ng/mL for Beta-2 Agonists, Hormone and Metabolic Modulators, Narcotics, Cannabinoids and Glucocorticoids, 0.1-14 ng/mL for Manipulation of blood and blood components, Beta Blockers, Anabolic Agents and Hypoxia-Inducible Factor (HIF) Acivting Agents, and 2.5-100000 ng/mL for substances of Appendix A, Diuretics & Masking Agents and Stimulants. The sample preparation is consisted of two part: one is the dilute & shoot part analyzed in UPLC-QQQ-MS, another is a mixture of the dilute & shoot part and a liquid-liquid extraction part of hydrolyzed human urine analyzed in UPLC-QE Plus-HRMS in full scan with polarity switching and parallel reaction monitoring (PRM) mode. The method has been fully validated for doping control purposes. All the substances were compliant with WADA's required 1/2 Minimum Requirement Performance Levels (MRPL) or Minimum Reporting Levels (MRL), and this method was successfully used in the 2022 Beijing Winter Olympic Games and Winter Paralympic Games for the anti-doping purpose.

spectroscopy,chemistry, analytical,food science & technology

Neurological diseases in pregnancy: an overview. Foreword.

Metabolic Pathway of Osilodrostat in Equine Urine Established through High-resolution Mass Spectrometric Characterization for Doping Control

Neuropsychological Test Performance Among Caribbean-born and U.S.-born African American Elderly: The Role of Age, Education and Reading Level

Pharmacokinetic study of osilodrostat and identification of mono‐hydroxylated metabolite in equine plasma for the purpose of doping control

Broad‐spectrum and sensitive screening of more than 1000 compounds in equine urine using liquid chromatography/high‐resolution mass spectrometry

Direct injection horse urine analysis for the quantification and identification of threshold substances for doping control. III. Determination of salicylic acid by liquid chromatography/quadrupole time-of-flight mass spectrometry

A Broad-Spectrum Peptide Screening Method Using an Optimized Solid-Phase Extraction and Liquid Chromatography–High-Field Asymmetric Ion Mobility Spectrometry–Mass Spectrometry for Doping Control in Equine Urine

Detection of FG‐4592 and metabolites in equine plasma, urine and hair following oral administration

Brain Microdialysis Study of Meropenem in Two Patients with Acute Brain Injury

A rapid and sensitive method for the quantitative analysis of ibuprofen and its metabolites in equine urine samples by gas chromatography with tandem mass spectrometry.

Investigation Into the Equine Metabolism of Phosphodiesterase‐4 Inhibitor Roflumilast for Potential Doping Control

Long-term followup of patients less than 30 years old with transitional cell carcinoma of bladder.

Mentoring Diversity. Serving a diverse patient population calls for diverse leadership.

Detection of methandienone and its metabolites in equine urine, plasma and hair following a multidose oral administration

Doping control analysis of myo‐inositol trispyrophosphate and 10 bisphosphonates in equine plasma by ion chromatography–mass spectrometry and its application to clodronic acid horse administration

Identification and differentiation of somapacitan, a long-acting growth hormone derivative, and recombinant human growth hormone in equine plasma by LC-HRMS for doping control purpose

Model-based boundary estimation of complex objects using hierarchical active surface templates

Development and validation of general plasma screening method for performance enhancing drugs in racehorses utilizing liquid chromatography-high-resolution mass spectrometry (LC-HRMS)

3-Methoxytyrosine as an indicator of dopaminergic manipulation in equine plasma

Analysis of corticosteroids in equine urine by liquid chromatography–mass spectrometry

A Comprehensive and High-Throughput Screening Multiple Prohibited Substances Method by UPLC-QE Plus-HRMS and HPLC-QQQ-MS in Human Urine for Doping Control